Actively Recruiting
Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy
Led by Centro Hospitalar de Lisboa Central · Updated on 2025-02-21
100
Participants Needed
1
Research Sites
46 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hydroxychloroquine retinal toxicity affects a significant number of patients using this medication. Detection of toxicity is difficult in the early stages of the disease and depends on the subjectivity of the clinician who reads the tests (optical coherence tomography, autofluorescence and visual fields). Automating the reading of these diagnostic exams could lead to earlier detection of this pathology and reduce the burden associated with interpreting these exams in the ophthalmology service. The images that are usually taken in the screening and monitoring of hydroxychloroquine toxicity by will be collected - photography of the ocular fundus and optical coherence tomography with autofluorescence.
CONDITIONS
Official Title
Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with > 10 years of HCQ intake
You will not qualify if you...
- Patients with ocular diseases that might mimic HCQ maculopathy or interfere with HCQ maculopathy screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Local de Saúde São José
Portugal, Portugal, 1150-199
Actively Recruiting
Research Team
R
Rita Anjos, MD
CONTACT
A
Ana Luisa Basílio, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here